News Related to Optogenetic Gene Therapy

Related coverage linked through entity extraction aliases.

Forge Biologics Partners with Restore Vision, Showcases Manufacturing at ASGCT, and Discusses AAV Expertise

Jul 21, 2026

Forge Biologics has partnered with Restore Vision to manufacture RV-001, a gene therapy for retinitis pigmentosa in Phase 1/2 trials in Japan. Forge also announced seven presentations at the ASGCT 29th Annual Meeting, highlighting process innovation and late-phase manufacturing capabilities. The company's CTO further discussed industrial-scale AAV gene therapy on The Genetics Podcast.

Ray Therapeutics Receives EMA PRIME Designation for RTx-015 Gene Therapy in Retinitis Pigmentosa

May 01, 2026

Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.